



RKGIT
(Pharmacy)



Pharmaware

A quarterly e-News Letter
Issue June 2022; Volume 26

Chief Patrons

Shri Dinesh Kumar Goel
Shri Akshat Goel

Patrons

Dr. Laxman Prasad
Dr. D.K. Chauhan
Dr. D.R. Somashekhar

Editor in Chief

Dr. Monika Sachdeva

Editor

Dr. Munendra Mohan Varshney

Chief Advisory Committee

Dr. Umesh Kumar Singh

Mr. H. G. Garg

Mr. Vipul Goel

Faculty Advisory Board

Mr. Abhinav Agrawal

Dr. Vishwanath Agrahari

Dr. Vijay Agarwal

Mr. Pankaj Kumar Sharma

Dr. Dilip Gupta

Dr. Manish Mishra

Ms. Geetika Mehra

Ms. Rashmi Tripathi

Ms. Rituparna Palit

Ms. Avantika Sharma

Dr. Neha Krishnarth

Dr. M.A. Sheela

Ms. Archana Gupta

Ms. Priya Tyagi

Ms. Rini singhal

Ms. Chaya Chauhan

Ms. Anjali Singh

Ms. Anshu Tripathi

Ms. Kamini

Ms. Anushika Jain

Ms. Farha Sultana

Student coordinators

Jai Prakash

Lovely Kaushik

VISION

To be recognized as a foremost institution imparting quality pharmacy education to aspiring pharmacists with right competencies, attitude, skills and knowledge, for the greater benefit of mankind.

MISSION

To produce highly qualified and motivated graduates possessing fundamental knowledge and soft skills, who can provide sustainable solutions to health care problems.

To develop partnerships with industries, eminent institutes and government agencies in the field of pharmaceutical sciences.

To serve the community, at local, national and international levels, with a deep awareness of our ethical responsibilities towards profession and society.

PROGRAM EDUCATIONAL OBJECTIVES

OUR GRADUATES SHOULD HAVE:-

1. Have quality theoretical knowledge and practical skills on all core and allied fields of pharmaceutical sciences, so that they can face the challenges of the globalized scenario and contribute to the progress of the nation.
2. Enjoy successful careers in all settings of Pharma sector, by engaging themselves in professional development through leadership, communication, skills, teamwork and entrepreneurship.
3. Function ethically and lawfully in professional environment and exhibit good competency in their work culture.
4. Act as a link between healthcare system and community, so as to serve the society by the transmitting their knowledge, with a sense of social responsibility.
5. Participate in continuing education

ALL INDIA 29th RANK IN NIRF-2016

AKTU APPROVED PHD RESEARCH CENTRE

NBA ACCREDITED (B.PHARM)

COVID SECTION

BOOSTER DOSE AGAINST COVID 19

The World Health Organization, with the support of the Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group, continues to review the emerging evidence on the need for and timing of additional booster doses for the currently available COVID-19 vaccines which have received Emergency Use Listing (EUL).

The evidence on additional booster doses is the objective of this study. In considering additional booster doses, there are two main scenarios to assess: 1) the use of additional booster doses in those who are not able to mount and sustain adequate immune responses and 2) considerations for additional booster doses to be administered in order to protect high risk populations and health workers in order to maintain the health system during periodic waves of disease surges.

Booster doses should be offered based on evidence that doing so would have substantial impact on reducing hospitalization, severe disease and death, and to protect health systems. The order of implementing booster doses to different population groups should follow that which has been laid out for the primary vaccination series – i.e., booster doses should be prioritized for higher priority-use groups before lower priority-use groups, unless there is adequate justification not to do so. Such justification may include programmatic constraints or acceptability obstacles to uptake in higher priority-use groups that would result in vaccine wastage. In such cases, strategies should be prioritized to improve vaccine delivery, community engagement, and social mobilization efforts to reach higher priority-use groups.

Additional booster doses beyond the first booster dose are currently being offered by some countries (i.e. fourth dose to older adults and a fifth dose for immune compromised persons). Data on the usefulness of these additional booster doses is sparse and especially limited on the duration of further protection. Data on additional booster doses as of May 2022 only exists for the mRNA vaccines, and not for other vaccine platforms. Hence, in the following report, emphasis on the evidence with regards to introduce additional booster for mRNA vaccines, while encouraging more data to be accrued for all vaccine platforms.

Reference: <https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19>

HERBAL INFORMATION

MARIGOLD

Botanical name: *Calendula officinalis*

Family: Asteraceae

Kingdom: Plantae



Marigold is a short-lived aromatic herbaceous perennial, growing to 80 cm tall, with sparsely branched lax or erect stems. The leaves are oblong-lanceolate, 5–17 cm (2–7 in) long, hairy on both sides, and with margins entire or occasionally waved or weakly toothed. It is widely cultivated and can be grown easily in sunny locations in most kinds of soils. It has no problem with nutritionally poor, very acidic or very alkaline soils, just as long as it's moist.

USES

Well known as a remedy for skin problems, the deep-orange flowered pot marigold variety is applied externally to

- bites
- stings
- sprains
- wounds
- sore eyes
- varicose veins
- Internally it is used to treat fevers and chronic infections.
- The tea of the petals tones up circulation and, taken regularly, eases varicose veins.
- Applying the crushed stems of marigold to corns and warts will soon have them easily removable.

Marketed Formulations:

1. CALENDULA PREPARATIONS



STUDENT CORNER

7 Hills Pharma's Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small molecules which augment the activity of a broad range of immunotherapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to 7HP349, 7HP’s lead clinical-stage immunostimulant, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.

FDA’s Fast Track program is intended to speed the development and expedite regulatory review of drugs that fulfill unmet medical needs in the treatment of serious conditions. Fast Track designation offers a variety of benefits to accelerate the development process, including more frequent meetings and correspondence with the FDA as well as eligibility for accelerated approval and priority review, assuming relevant criteria are met.

7HP349 is designed as an oral therapy to be used in combination with an immunotherapy to improve the effectiveness of potentially any immunotherapeutic, including, but not limited to immune checkpoint inhibitors (ICI) and infectious disease vaccines, through a unique mechanism of action. 7HP349 is an allosteric activator of the integrins VLA-4 and LFA-1, which are essential elements in the generation of an effective antigen-specific immune response. These integrins underlie rate-limiting steps in lymphocyte recruitment, extravascular trafficking, T cell activation and effector functions. Following a successful first-in-human Phase I clinical trial completed in 4Q2021, 7HP349 will be entering Phase Ib/IIa trials in PD-1 refractory solid tumors and influenza vaccination of the elderly.

“FDA’s decision to grant 7HP349 Fast Track designation underscores the critical unmet medical need still present in anti-PD-1-resistant melanoma. Main focus is to bring oncologists a completely new therapeutic modality to overcome ICI resistance. Achieving Fast Track designation for our lead clinical molecule represents a meaningful step toward our goal of delivering the full promise of immunotherapy,” said Dr. William Schary, 7 Hills VP of Clinical and Regulatory Affairs.

7HP349 has been recognized by the FDA as a potential solution to substantively improve upon current state-of-the-art cancer immunotherapy and have opportunity to accelerate developmental plans through enhanced flexibility and communication with FDA.

ANJALI SHARMA, HIMANSHU TYAGI, JAI PRAKASH SINGH

(B. PHARM, 3rd YEAR)

REFERENCE

Google & Yahoo finance, Pharma news and research sites.

NEWS AT A GLANCE

TALK ORGANIZED


Mantra for Success and Happiness

RKGIT (Pharmacy) organized online talk on “Mantra for Success and Happiness” On 13.5.2022. The talk was delivered by Dr. Arvind Gupta, Managing Director, Pharma Synth Formulations.



Radiation Therapy for Cancer

RKGIT (Pharmacy) organized online talk on “Radiation Therapy for Cancer” On 21.5.2022. The talk was organized specifically for B.Pharm. Illrd year to fill the course gap for the Pharmacology-III. Dr. Sanket Pandey, MD, Radiation Oncologist, Apollo Super specialty Hospital, Lucknow delivered the lecture on radiation therapy: Applications in cancer patients.



Leadership in Higher Education and Pedagogy

RKGIT (Pharmacy) organized online talk on “Leadership in Higher Education and Pedagogy” on 21.6.22. The talk was delivered by Dr. B. N. Sinha, Professor, BIT, Mesra to Pharmacy students and faculty.



VISIT

Hamdard Laboratories

On 29.4.2022, An industrial visit to Hamdard laboratories was organized by RKGIT (Pharmacy) for Students of Pharm VIII Semester and M.Pharm II & IV Semester. Mr. S.K. Joshi, Head R&D, Hamdard laboratories explained each section of the industry in detail. It was an excellent learning experience for all the students.




Visit to Primary Health Care

RKGIT (Pharmacy) organized a visit to Primary Health Care, Kakra block, Muradnagar On 2.5.2022, 4.5.2022 and 6.5.2022, The visit was organized for Diploma 1st year students. Chief Pharmacist Mr. Sachin Kumar demonstrated various facilities and department of the healthcare center. The students were apprised of the essential medicine list, procurement, dispensing and storage of medicines, maintenance of the stock register and other required document. They were also told about the ethical responsibility of this noble profession.




BOOKS PUBLISHED


Author Dr. Neha Krishnarth (Assistant professor) and Ms. Chhaya Chauhan (Assistant professor) published the book "Pharmaceutical Chemistry" under Pee Vee publications As per Syllabus framed under Education Regulation 2020 prescribed for D. Pharm, First Year by Pharmacy Council of India (PCI).



Author Dr. Neha Krishnarth (Assistant professor) published the book "Pharmaceutical Organic Chemistry-II" under Pritam Publications As per PCI Syllabus for B.Pharm 3rd Sem.



Mrs. Anshu Tripathi (Assistant professor) published a book chapter entitled "Resins and their uses" in the book "Moderns Trends in Pharmaceutical Sciences in India"



STUDENT'S ACHIEVEMENT

GPAT-2022 Qualified

RKGIT (Pharmacy) congratulates Shivam Tyagi for qualifying GPAT-2022 with NTA Score 97.798 and AIR-1116. He has also cleared NIPER JEE (Rank 792).



PHARMAPRENEUR

Innovation Hub, in association with Dr. APJ Abdul Kalam Technical University, organized an Innovative Pitch-in Session for Pharmacy Students "PHARMAPRENEURS" ON 24th May 2022. This ideation contest received overwhelmingly eighty applications from various pharmacy student teams across the state. Out of which Top-20 ideas were shortlisted for a pitch-in session by esteemed jury members. This program was envisioned by the Honorable Vice-Chancellor Prof. P.K. Mishra who himself is an expert in Biotechnology and have been working on multiple socially relevant ideas. The winners of PHARAMAPRENEURS program were Team of Ms. Sarika Singh with team-members, Ankit Kumar Sharma, Nikhil Kumar and Parikshit Sachdeva from RKGIT, Ghaziabad who were awarded Laptop.



Anjanaya Gupta secured 2nd position in monoact at Galgotia Unifest 2022 on 11th April 2022. He Performed Monoact on Terrorism.He competed with the students of Galgotia College, AKG, Delhi University, Jawaharlal Nehru University, and other University students.Based on his hard work and impressive act he successfully secured second position for RKGIT.

FAREWELL ORGANIZED

Students of B.Pharm VI Semester and M.Pharm II Semester have organised farewell for their senior batches on 14th May,2022.Akshat, student of B.Pharm VI Semester and Manan, student of M.Pharm II semester coordinated the programme.It was the morning of mixed emotions for all present at the college to witness the official send-off for the students at the Farewell ceremony. The day was a fiesta devoted to the years spent together with friends and teachers to reminisce joyous moments.

Following are the titles won by students at their farewell (B.Pharm)

1. Mr. and Miss Farewell - Aryan Bhardwaj &Ishika Tyagi
2. Mr. and Miss stylish - Chirag Tyagi & Kirti Tiwari
3. Mr. All-rounder - Manan Bhasin
4. Mr. Best Attire - Navneet Chaudhary

Following are the titles won by students at their farewell for (M.Pharm.)

1. Miss Farewell - Neha Varshney
2. Mr. Farewell - Mukesh Bansal
3. Million Dollar Smile - Preeti Singh
4. Miss Best Attire - Pallavi Khandpal



REGARDS

Pharmaware Team

For Views and Suggestions

Connect

epharmaware@gmail.com

*Raj Kumar Goel Institute of Technology (Pharmacy),
5th KM Stone, Delhi-Meerut Road, Ghaziabad, U.P. 201003, Ph. 9582945609*